ES2526816A1 - Compositions for the treatment of liver damage - Google Patents

Compositions for the treatment of liver damage Download PDF

Info

Publication number
ES2526816A1
ES2526816A1 ES201330895A ES201330895A ES2526816A1 ES 2526816 A1 ES2526816 A1 ES 2526816A1 ES 201330895 A ES201330895 A ES 201330895A ES 201330895 A ES201330895 A ES 201330895A ES 2526816 A1 ES2526816 A1 ES 2526816A1
Authority
ES
Spain
Prior art keywords
liver damage
compositions
treatment
stimulate
survival
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201330895A
Other languages
Spanish (es)
Other versions
ES2526816B1 (en
Inventor
Yolanda ALMADÉN PEÑA
Carmen HERENCIA BELLIDO
Juan Rafael MUÑOZ CASTAÑEDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
Universidad de Cordoba
Fundacion Publica Andaluza Progreso y Salud
Original Assignee
FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
Universidad de Cordoba
Fundacion Publica Andaluza Progreso y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA, Universidad de Cordoba, Fundacion Publica Andaluza Progreso y Salud filed Critical FUNDACION PARA LA INVESTIGACION BIOMEDICA DE CORDOBA
Priority to ES201330895A priority Critical patent/ES2526816B1/en
Priority to PCT/ES2014/070497 priority patent/WO2014198996A1/en
Publication of ES2526816A1 publication Critical patent/ES2526816A1/en
Application granted granted Critical
Publication of ES2526816B1 publication Critical patent/ES2526816B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E06—DOORS, WINDOWS, SHUTTERS, OR ROLLER BLINDS IN GENERAL; LADDERS
    • E06B—FIXED OR MOVABLE CLOSURES FOR OPENINGS IN BUILDINGS, VEHICLES, FENCES OR LIKE ENCLOSURES IN GENERAL, e.g. DOORS, WINDOWS, BLINDS, GATES
    • E06B9/00—Screening or protective devices for wall or similar openings, with or without operating or securing mechanisms; Closures of similar construction
    • E06B9/02—Shutters, movable grilles, or other safety closing devices, e.g. against burglary
    • E06B9/08—Roll-type closures
    • E06B9/11—Roller shutters
    • E06B9/17—Parts or details of roller shutters, e.g. suspension devices, shutter boxes, wicket doors, ventilation openings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Structural Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Architecture (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Civil Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of the intracellular content of individual mesenchymal stem cells with acute liver damage in order to stimulate the survival, regeneration and/or repair of the damaged organ. The invention also relates to the use of this lysate for the production of a pharmaceutical composition comprising said intracellular content, intended to stimulate the survival, regeneration and/or repair of organs, specifically the liver.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

Claims (1)

imagen1image 1
ES201330895A 2013-06-14 2013-06-14 Compositions for the treatment of liver damage Expired - Fee Related ES2526816B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201330895A ES2526816B1 (en) 2013-06-14 2013-06-14 Compositions for the treatment of liver damage
PCT/ES2014/070497 WO2014198996A1 (en) 2013-06-14 2014-06-16 Compositions for the treatment of liver damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330895A ES2526816B1 (en) 2013-06-14 2013-06-14 Compositions for the treatment of liver damage

Publications (2)

Publication Number Publication Date
ES2526816A1 true ES2526816A1 (en) 2015-01-15
ES2526816B1 ES2526816B1 (en) 2015-10-27

Family

ID=51033224

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330895A Expired - Fee Related ES2526816B1 (en) 2013-06-14 2013-06-14 Compositions for the treatment of liver damage

Country Status (2)

Country Link
ES (1) ES2526816B1 (en)
WO (1) WO2014198996A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8172784B2 (en) * 2006-10-11 2012-05-08 The General Hospital Corporation Compositions, methods, and devices for treating liver disease
ES2423483T3 (en) * 2007-10-29 2013-09-20 Fresenius Medical Care Deutschland Gmbh Use of microvesicles (MV) derived from stem cells to prepare a drug for endothelial / epithelial regeneration of damaged or damaged tissues or organs, and related methods in vitro and in vivo

Also Published As

Publication number Publication date
WO2014198996A1 (en) 2014-12-18
ES2526816B1 (en) 2015-10-27

Similar Documents

Publication Publication Date Title
LTC3057969I2 (en) COMPOSITIONS USED IN THE TREATMENT OF DISORDERS ASSOCIATED WITH KIT
UA117008C2 (en) CFTR mRNA COMPOSITIONS AND RELATED METHODS AND USES
CO2020015153A2 (en) Rip1 Inhibitor Compounds and Methods for Making and Using Them
CL2016001547A1 (en) Compositions for oral care
ES2637421T3 (en) Topical compositions comprising fold-OB variants
CL2015000829A1 (en) Histone Demethylase Inhibitors
MX2015009105A (en) Solid solution compositions and use in chronic inflammation.
MX366317B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
UY34200A (en) 3- (FLUOROVINIL) PIRAZOLES AND ITS USE
AR102203A1 (en) COMPOSITIONS FOR ORAL CARE THAT INCLUDE ZINC, ARGININA AND SERINA
ES2508165T3 (en) Lactoferrin and white matter
CR20150653A (en) NEW COMPOUNDS FOR CANCER TREATMENT
CL2016000026A1 (en) New azabenzimidazole derivatives
ECSP17015154A (en) METHODS TO IMPROVE MYOCARDIAL PERFORMANCE IN PATIENTS WITH FONTAN SURGERY USING UDENAFILO COMPOSITIONS
ES2660019T3 (en) Patch containing diclofenac and thiocolchicose
JP2015016294A5 (en)
IT201700037319A1 (en) NATURAL COMPOSITION FOR USE IN GYNECOLOGY
BR112015016995A8 (en) use of nicotinic acetylcholine alpha 7 receptor agonists
JP2013241986A5 (en)
ES2536842T3 (en) Pharmaceutical composition for cancer treatment
UY34340A (en) PLANTS THAT HAVE TRACKS RELATED TO STRESS AND METHODS TO PRODUCE THE SAME.
ES2526816A1 (en) Compositions for the treatment of liver damage
CL2015003535A1 (en) Pharmaceutical compositions
ES2573354A1 (en) Lysates of mesenchymal stem cells for the treatment of musculoskeletal injuries (Machine-translation by Google Translate, not legally binding)
ES2478692A1 (en) Liquid carbocisteine formulations having improved properties

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2526816

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20151027

FD2A Announcement of lapse in spain

Effective date: 20211202